Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story

Simply Wall St.05-22

Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures. The new system expands BD’s urologic stone management portfolio and is now available in the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2637345276?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694","is_english":true,"pubTime":"2026-05-22 23:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2637345276","market":"us","top_or_hot":-1,"title":"Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story","media":"Simply Wall St.","content":"<div>\n<p>Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures. The new system expands BD’s urologic stone management portfolio and is now available in the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/elyra-kidney-stone-laser-launch-tests-becton-dickinson-execu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-22 23:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/elyra-kidney-stone-laser-launch-tests-becton-dickinson-execu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures. The new system expands BD’s urologic stone management portfolio and is now available in the ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/elyra-kidney-stone-laser-launch-tests-becton-dickinson-execu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1059921491.USD","symbol_name":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/elyra-kidney-stone-laser-launch-tests-becton-dickinson-execu","article_id":"2637345276","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/103678-main-header/1756253637694"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bdx/becton-dickinson/news/elyra-kidney-stone-laser-launch-tests-becton-dickinson-execu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2637345276","pubTimestamp":1779463950,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures.\nThe new system expands BD’s urologic stone management portfolio and is now available in the United States.\nThe launch is aimed at supporting procedural efficiency and workflow for urology teams treating kidney stones.\n\nBecton Dickinson, trading at around $146.25 per share, is adding the Elyra Thulium Fiber Laser System to its existing kidney stone care portfolio. For investors tracking...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0068578508.USD":"First Eagle Amundi International Cl AU-C USD","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","BK4082":"医疗保健设备","LU1150488218.USD":"First Eagle Amundi Income Builder AU2-MD USD","BK4504":"桥水持仓","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","BK4588":"碎股","SGY":"斯通能源","LU0162691827.USD":"BGF US BASIC VALUE \"A4\" INC","BDX":"碧迪医疗","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU1150488135.SGD":"First Eagle Amundi Income Builder AHS-MD SGD-H","LU0072461881.USD":"BGF US BASIC VALUE \"A2\" ACC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0985489474.SGD":"First Eagle Amundi International AHS-C SGD-H","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0878866978.SGD":"First Eagle Amundi International AHS-QD SGD-H","LU1489326972.SGD":"First Eagle Amundi International AHS-MD SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0433182093.SGD":"First Eagle Amundi International AS-C SGD"},"translate_title":"Elyra肾结石激光发射测试Becton Dickinson执行故事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGY":1.5,"BDX":1.5},"content_text":"Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures. The new system expands BD’s urologic stone management portfolio and is now available in the United States. The launch is aimed at supporting procedural efficiency and workflow for urology teams treating kidney stones.  Becton Dickinson, trading at around $146.25 per share, is adding the Elyra Thulium Fiber Laser System to its existing kidney stone care portfolio. For investors tracking NYSE:BDX, this launch comes within a mixed return profile, with the stock up 10.5% over the past year but down 18.6% over three years and down 13.9% over five years. The move reflects continued product development in a focused clinical area rather than broad portfolio reshaping. Looking ahead, readers may want to watch how quickly urology centers adopt the Elyra system and how it is integrated with BD’s existing stone management tools. Uptake, procedural volume and customer feedback could all influence how meaningful this launch becomes within BD’s larger medical technology franchise. Stay updated on the most important news stories for Becton Dickinson by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Becton Dickinson. NYSE:BDX 1-Year Stock Price Chart See which insiders are buying and buying and selling Becton Dickinson following this latest news. The Elyra Thulium Fiber Laser launch extends BD’s urology offering at a time when investors are already weighing product execution, a microbiology pouch recall and new leadership in BD Interventional. For holders of NYSE:BDX, this adds another procedure-focused platform that sits alongside Foley catheters, infection prevention products and other interventional tools, which can matter for hospital purchasing decisions and contract depth. The recall of BD GasPak EZ systems highlights that quality and regulatory oversight remain front of mind, so some investors may see Elyra as a test case for how effectively BD can introduce new technology while maintaining product reliability. The recent €600 million fixed income issue to refinance 2026 notes also shows BD is active on the balance sheet side while it refreshes parts of the portfolio. In the short term, share price reaction may depend less on the headline of a new laser and more on evidence that Elyra adoption, recall management and execution under incoming BD Interventional president Peter Menziuso move in the same direction. AdvertisementHow This Fits Into The Becton Dickinson Narrative  The Elyra system lines up with the narrative focus on procedure-centric devices and recurring use in chronic care, supporting the idea of a consumables heavy, clinically oriented portfolio. Execution risk around recalls and product quality in microbiology adds a counterpoint to the thesis that operational programs alone can steadily improve margins and reliability. The specific impact of a kidney stone laser platform and related capital spending choices by hospitals may not be fully captured in broad assumptions about product launches across diagnostics and advanced therapies.  Knowing what a company is worth starts with understanding its story.\n Check out one of the top narratives in the Simply Wall St Community for Becton Dickinson to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ Quality and regulatory risk is in focus after the ongoing Class II recall of BD GasPak EZ pouch systems, which could weigh on sentiment if similar issues appear elsewhere. ⚠️ BD carries a high level of debt, and new fixed income offerings add refinancing obligations that investors may track alongside any slowdown in product traction. 🎁 BD has 6 identified rewards, including trading below some fair value estimates and expectations for earnings growth, which may appeal to investors looking at medtech peers such as Medtronic, Boston Scientific and Abbott Laboratories. 🎁 The expanding urology and infection prevention portfolio, including Elyra and Bactiguard coated Foley catheters, supports a story of breadth across procedure areas that can matter in hospital vendor selection.  What To Watch Going Forward From here, keep an eye on early usage patterns for Elyra in US urology centers, feedback from clinicians on workflow and stone management outcomes, and whether the system gains traction alongside competing laser platforms from peers. Monitor updates on the microbiology pouch recall to see how quickly BD closes out corrective actions, as that will inform views on quality control. The first few quarters of Peter Menziuso’s tenure running BD Interventional will also be important for understanding how tightly new launches, margin goals and capital allocation are aligned. To ensure you're always in the loop on how the latest news impacts the investment narrative for Becton Dickinson, head to the\n community page for Becton Dickinson to never miss an update on the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Becton Dickinson might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2637345276","isCrawlerRequest":true}